Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Genitourinary 1

Conditions

Prostatic Neoplasms 3Recurrence 2Small Cell Lung Carcinoma 1Metastatic Castration-Resistant Prostate Cancer 1Lymphoma, Follicular 1Adenocarcinoma 1

Interventions

Cyclophosphamide 9fludarabine 7Dexamethasone 7pomalidomide 6Rituximab 6pembrolizumab 5selinexor 4obinutuzumab 4glofitamab 4Lenalidomide 4daratumumab 3belantamab mafodotin 3Temozolomide 3Gemcitabine 3Etoposide 3Bortezomib 3zanubrutinib 2venetoclax 2tocilizumab 2fludarabine phosphate 2enzalutamide 2cemiplimab 2carfilzomib 2abemaciclib 2PF06821497 2Mesna 2Lisaftoclax 2Injections 2Immunotherapy, Adoptive 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × PF06821497 × 30 days × Clear all
NCT03460977 2026-05-20

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Pfizer

Phase 1 Recruiting
453 enrolled
LymphoidThoracic

Lymphoma, Follicular, Recurrence, Small Cell Lung Carcinoma

NCT06551324 2026-05-05

MEVPRO-1

Pfizer

Phase 3 Active not recruiting
600 enrolled
Genitourinary

Prostatic Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡